Targeting Ras and Rho GTPases as opportunities for cancer therapeutics

Walker, K. and Olson, M. (2005) Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Current Opinion in Genetics and Development, 15(1), pp. 62-68. (doi: 10.1016/j.gde.2004.11.001) (PMID:15661535)

Full text not currently available from Enlighten.

Abstract

The Ras and Rho GTPases contribute to the initiation and progression of cancer by subverting the normal regulation of specific intracellular signalling pathways. As a result, Ras and Rho play significant roles in the development of numerous aspects of the malignant phenotype by promoting cell cycle progression, resistance to apoptotic stimuli, neovascularisation and tumour cell motility, invasiveness and metastasis. With these GTPases contributing at so many levels, they are appealing targets for the development of cancer chemotherapeutic agents.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Olson, Professor Michael
Authors: Walker, K., and Olson, M.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Current Opinion in Genetics and Development
Publisher:Elsevier
ISSN:0959-437X
Published Online:19 November 2004

University Staff: Request a correction | Enlighten Editors: Update this record